Pacer Advisors Inc. Has $410,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Pacer Advisors Inc. decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 96.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,766 shares of the company's stock after selling 897,979 shares during the quarter. Pacer Advisors Inc.'s holdings in Takeda Pharmaceutical were worth $410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Raymond James & Associates raised its stake in Takeda Pharmaceutical by 34.6% in the 4th quarter. Raymond James & Associates now owns 222,369 shares of the company's stock valued at $3,173,000 after purchasing an additional 57,134 shares during the last quarter. Legacy Wealth Asset Management LLC raised its stake in Takeda Pharmaceutical by 24.5% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 155,528 shares of the company's stock valued at $2,219,000 after purchasing an additional 30,561 shares during the last quarter. Bruce G. Allen Investments LLC acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $138,000. Citigroup Inc. increased its stake in shares of Takeda Pharmaceutical by 5.6% during the 3rd quarter. Citigroup Inc. now owns 57,941 shares of the company's stock valued at $896,000 after acquiring an additional 3,089 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Takeda Pharmaceutical by 6.3% during the 3rd quarter. American Century Companies Inc. now owns 211,934 shares of the company's stock valued at $3,279,000 after acquiring an additional 12,647 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Up 1.0 %

Shares of NYSE TAK traded up $0.14 on Friday, reaching $13.62. 1,822,599 shares of the company traded hands, compared to its average volume of 1,562,323. Takeda Pharmaceutical Company Limited has a fifty-two week low of $13.19 and a fifty-two week high of $17.15. The company has a 50 day moving average of $14.36 and a 200 day moving average of $14.43. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $43.10 billion, a PE ratio of 20.64, a P/E/G ratio of 3.81 and a beta of 0.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion during the quarter. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company's stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the completion of the transaction, the insider now owns 3,755,583 shares of the company's stock, valued at approximately $30,420,222.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.04% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.